Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients [0.03%]
斯波利单抗：一种新型白介素-36抑制剂，用于治疗成人泛发性脓疱型银屑病的急性发作
Tuba Bukhari,Mariya Markovina,Abrahim Abduelmula et al.
Tuba Bukhari et al.
Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pa...
Review
Skin therapy letter. 2024 Jan;29(1):1-4. DOI: 2024
Ayaa Alkhaleefa,Taylor Evart Woo,Laurie Parsons
Ayaa Alkhaleefa
Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by the presence of pruritic nodules. Dupilumab was approved by the US Food and Drug Administration in September 2022 and Health Canada in July 2023 for the treatm...
Karla Machlab,Jensen Yeung,Melinda Gooderham
Karla Machlab
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. Its major clinical domains include peripheral and axial arthritis, enthesitis, dactylitis and skin and nail involvement. Approximately 30...
A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology [0.03%]
皮肤病学 topical药物递送系统的实用指南
Andrei Metelitsa,Isabelle Delorme,Daniel O&#x;Sullivan et al.
Andrei Metelitsa et al.
Dermatological diseases such as atopic dermatitis, acne, and psoriasis result in significant morbidity and decreased quality of life. The first line of treatment for such diseases is often topical medications. While topical delivery allows ...
Review
Skin therapy letter. 2023 Sep;28(5):5-11. DOI: 2023
Ashley O&#x;Toole,Melinda Gooderham
Ashley O&#x;Toole
Roflumilast is a highly selective phosphodiesterase-4 inhibitor for the treatment of plaque psoriasis. Topical roflumilast 0.3% cream, approved by the US FDA and Health Canada for use in adolescents and adults, has proven efficacy and toler...
Review
Skin therapy letter. 2023 Sep;28(5):1-4. DOI: 2023
Lyn Guenther
Lyn Guenther
The lifetime risk for herpes zoster (HZ) of approximately 1 in 3 is increased with advancing age, a family history of HZ, diseases with altered immune function, immunosuppression, physical trauma and psychological stress. In dermatology, mo...
Nicole Salame,Ariel E Eber,Jeffrey Dover
Nicole Salame
Botulinum toxin A (BoNTA) is produced by Clostridium botulinum and widely used for aesthetic indications requiring neuromuscular blockade. For dynamic facial lines, BoNTA is effective and safe, but also temporary, requiring repeat injection...
Review
Skin therapy letter. 2023 Jul;28(4):1-3. DOI: 2023
Nadia Kashetsky,Irina Turchin
Nadia Kashetsky
As systemic administration of Janus kinase-inhibitors is associated with safety concerns, local alternatives, such as topical ruxolitinib, have been developed. This review summarizes utilization of topical ruxolitinib in dermatology. A lite...
Review
Skin therapy letter. 2023 May;28(3):8-13. DOI: 2023
The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions [0.03%]
治疗斑秃的Janus激酶抑制剂药物进展及未来方向展望
Jeff Donovan
Jeff Donovan
Oral Janus kinase (JAK) inhibitors now have a position as first-line agents for treating advanced alopecia areata. Oral JAK inhibitors are considerably more effective than topical JAK inhibitors, although topical agents may still have a val...
Review
Skin therapy letter. 2023 May;28(3):1-7. DOI: 2023
Austinn C Miller,Susuana Adjei,Laurie A Temiz et al.
Austinn C Miller et al.
Virtually any antibiotic can be used in dermatology given the broad range of conditions treated. With the widespread use of antibiotics and the rapid emergence of resistant organisms, it is important to understand how dermatologists can com...